Dear Colleagues,
In this newsletter we would like to focus on adherence to pharmacological treatment: how can we improve? Adherence to statin treatment has previously been discussed in the journal. In a paper from Dr Drexel’s group in Austria, the authors related statin adherence and LDL-cholesterol target. In this issue a study by Dopheide et al presents adherence to statin therapy favouring survival of patients with symptomatic peripheral artery disease.
The relevance of depressive symptoms for the outcome of patients receiving vitamin K antagonists is reported by dr. Michal and collegues. Depressive symptoms and non-adherence to treatable cardiovascular risk factors’ medications in the CONSTANCES cohort is presented by Hamieh et al.
Aherence to pharmocotherapy in heart failure/cardiomyopathy is presented in two articles in this journal.
The last review in the trilogy on RCTs have previously been dedicated to the selection of endpoints as well as to reasons for premature stopping of RCTs. The last review is being published online and is focusing on “Subgroup analyses in randomized clinical trials: Value and limitations”.
Find more on our publication page.
In relation to our educational programme/courses, the Pharmacotherapy in Older People course is held 14-15 October 2021.
The All About Clinical Trials course will be run in 16-17 December 2021.
We will launch a new educational programme early 2022 termed “Cardiovascular Pharmacotherapy in women”.
More information on our educational training programme page.
Finally, here is our selection of ESC Congress recommended sessions.
On behalf of the Working Group nucleus,
Alexander Niessner, Chairperson 2020-2022 and
Anne Grete Semb, Communication Coordinator 2020-2022
Back to other news from the ESC Working Group on Cardiovascular Pharmacotherapy
Our mission: To reduce the burden of cardiovascular disease.